PipelineReview.com2h
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating ...
Armed robbery in Revesby5h
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
BioWorld17h
Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
MedPage Today21h
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...
ENDPOINTS NEWS21h
Pfiz­er touts blad­der can­cer re­sults as first ad­vance­ment for some pa­tients 'in decades'
Pfiz­er said its ex­per­i­men­tal an­ti-PD-1 drug best­ed the cur­rent stan­dard of care in a type of blad­der can­cer where ...
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...